Roche to acquire U.S. cancer drugmaker Ignyta in $1.7billion deal

Swiss drugmaker Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden its oncology portfolio globally, the companies said on Friday.

Roche would pay $27 per share for Ignyta, representing a premium of about 74 percent to the stock’s closing price on Thursday, they said.

Ignyta will continue its operations in San Diego and will be responsible for the ongoing pivotal study of entrectinib, its most advanced drug.

The U.S. company has a suite of drugs in early stage development that use gene therapy to kill off the underlying diseases that drive cancer tumor growth.

The deal is expected to close in the first half of 2018, the companies said.

Citi advised Roche on the deal, while BofA Merrill Lynch and J.P. Morgan Securities LLC advised Ignyta.

Sidley Austin LLP and Latham & Watkins LLP were legal counsel to Roche and Ignyta, respectively.

One thought on “Roche to acquire U.S. cancer drugmaker Ignyta in $1.7billion deal

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s